303 related articles for article (PubMed ID: 31294646)
1. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
[TBL] [Abstract][Full Text] [Related]
2. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Sun L; McDonnell D; von Moltke L
Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine/Samidorphan: First Approval.
Paik J
Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
[TBL] [Abstract][Full Text] [Related]
5. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
[TBL] [Abstract][Full Text] [Related]
7. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Sun L; Yagoda S; Yao B; Graham C; von Moltke L
Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
Corrao MM; Nelson LA
CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
Sun L; Mills R; Sadler BM; Rege B
J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
[TBL] [Abstract][Full Text] [Related]
11. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
[TBL] [Abstract][Full Text] [Related]
13. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
Gao J; Li J; Lu X; Yang J
Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
[TBL] [Abstract][Full Text] [Related]
14. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.
Toledo FGS; Martin WF; Morrow L; Beysen C; Bajorunas D; Jiang Y; Silverman BL; McDonnell D; Namchuk MN; Newcomer JW; Graham C
Neuropsychopharmacology; 2022 Feb; 47(3):696-703. PubMed ID: 34887529
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Faden J; Serdenes R; Citrome L
Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
[TBL] [Abstract][Full Text] [Related]
16. Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.
McIntyre RS; Citrome L; Cummings H; Todtenkopf MS; Tan LA; White M; Akerman S
CNS Spectr; 2023 Jun; 28(3):288-299. PubMed ID: 35236531
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
Sun L; von Moltke L; Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):106-114. PubMed ID: 31919994
[TBL] [Abstract][Full Text] [Related]
18. In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations.
Tan LA; Gajipara N; Sun L; Bacolod M; Zhou Y; Namchuk M; Cunningham JI
Neuropsychiatr Dis Treat; 2022; 18():2497-2506. PubMed ID: 36345421
[TBL] [Abstract][Full Text] [Related]
19. Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats.
Burke NN; Li Y; Deaver DR; Finn DP; Roche M; Eyerman DJ; Sanchez C; Kelly JP
J Psychopharmacol; 2019 Dec; 33(12):1620-1627. PubMed ID: 31512988
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine and samidorphan combination treatment: A systematic review.
Jawad MY; Alnefeesi Y; Lui LMW; Ceban F; Chen-Li DCJ; Teopiz K; Jaberi S; Gillissie ES; Vincenzo JDD; Rosenblat JD; McIntyre RS
J Affect Disord; 2022 Mar; 301():99-106. PubMed ID: 35007644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
